Improving Treatment Strategies for Patients with Follicular Lymphoma: How to Translate Novel Study Data into Clinical Practice

This satellite symposium took place on 13th June 2017 as a part of the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland

Chairperson: Bruce Cheson1
Speakers: Rosmarie Pfau,2 Mathias Rummel,3 Andrew Davies,4 Gilles Salles5

1. Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington DC, USA
2. Board Member of the Lymphoma Coalition Worldwide Network of Lymphoma;
President of HO/NOHO, Aesch, Switzerland
3. Med. Clinic IV for Hematology and Oncology, Hospital of the Justus-Liebig University, Giessen, Germany
4. Cancer Sciences Division, University of Southampton School of Medicine, Southampton, UK
5. Lyon-Sud University Hospital, Lyon, France

Disclosure: Prof Cheson reports fees for consulting and research support for his institution from HLR, Pharmacyclics, and Abbvie, and research support for his institution from Gilead and TG Therapeutics. Prof Rummel reports having received a research grant and honorarium from Roche. Dr Davies reports being the Associate Clinical Director of Southampton Clinical Trials Unit; being a member of the Advisory Boards of Roche, Gilead, Takeda, CTI, Mundipharma, and Karyopharma; having received research support from Roche, Gilead, Takeda, GSK, Bayer, Janssen, Karyopharma, and Pfizer; having received honoraria from Roche, Gilead, Takeda, CTI, Mundipharma, Janssen, and Pfizer; and receiving travel support from Takeda, CTI, and Mundipharma. Prof Salles reports personal compensation from Amgen, BMS, Celgene, Gilead, Janssen, Kite, Merck, Morphosys, Novartis, Roche, and Servier for consultancy, participation at symposia, or participation on advisory boards. Prof Salles also reports a research grant from Roche. Ms Pfau declares no conflicts of interest.
Acknowledgements: Writing assistance was provided by Dr Blair Hesp CMPP, ApotheCom, London, UK.
Support: This satellite symposium and this EMJ article was sponsored by F. Hoffmann-La Roche AG. Authors received honoraria for preparation and delivery of their presentations at the symposium. The views and opinions expressed in this article do not necessarily represent the views and opinions of the speakers or of Roche.
Citation: EMJ Hematol. 2017;5[1][Suppl 10]:2–10.

Meeting Summary

Prof Bruce Cheson opened the symposium by highlighting the unmet needs for patients with follicular lymphoma (FL) and the potential application of prognostic scores, imaging techniques, and genomics to stratify patients. Ms Rosmarie Pfau detailed the challenges faced by patients with FL around the world, particularly a desire for improved quality of life (QoL) and effective treatments with less toxicity. Prof Mathias Rummel discussed modern methods of assessing FL risk and predicting treatment outcomes, particularly regarding endpoint selection for clinical trials. Dr Andrew Davies presented data from the GALLIUM study, showing that obinutuzumab-chemotherapy and maintenance is superior to rituximabchemotherapy and maintenance in untreated advanced FL patients, while Prof Gilles Salles provided insight into future options being developed for patients with FL.

Click below to view the following videos:

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 148KB)

Comments are closed.